<DOC>
	<DOCNO>NCT02454010</DOCNO>
	<brief_summary>The purpose study determine safety tolerability subject receive FF-21101 ( 111In ) dosimetry FF-21101 ( 90Y ) treatment advance solid tumor .</brief_summary>
	<brief_title>A Dose Escalation Study Radio-labeled Antibody Treatment Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Males female ≥ 18 year age Histologically cytologically confirm advanced solid tumor malignancy , refractory relapse prior therapy , alternative therapy available At least 4 week beyond last chemotherapy ( ≥ 5 halflives target agent , whichever short ) , radiotherapy , major surgery experimental treatment recover acute toxicity ( ≤ Grade 1 ) Archival tumor sample available , willing undergo fresh tumor biopsy , prior study At least one measurable disease site meet target lesion requirement Adequate performance status : Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 Life expectancy ≥ 3 month Adequate hematologic parameter without ongoing transfusional support : Hemoglobin ( Hb ) ≥ 10 g/dL Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9 cells/L Platelets ≥ 150,000 x 10^6 cells/L Adequate renal hepatic function : Creatinine ≤ 1.5x upper limit normal ( ULN ) , calculate creatinine clearance ≥ 60 mL/minute x 1.73 m^2 per CockcroftGault formula Total bilirubin &lt; 1.5 time ULN unless due Gilbert 's disease ALT/AST ≤ 2.5 time ULN , &lt; 5 time ULN subject liver metastasis QT interval correct rate ( QTc ) ≤ 480 msec electrocardiogram ( ECG ) obtain Screening ( average 3 reading ) Negative serum pregnancy test Ability provide write informed consent Previous radioimmunotherapy . Previous antibodybased therapy allow long ≥ 28 day elapse last dose study treatment . Prior radiation &gt; 30 % red marrow maximal tolerable level organ Serious cardiac condition within last 6 month Concomitant medication ( ) may cause QTc prolongation induce Torsades de Pointes , exception antimicrobial consider essential care patient History retinal degenerative disease , history uveitis , history retinal vein occlusion ( RVO ) , eye condition would consider risk factor RVO medically relevant abnormality identify screen ophthalmologic examination Active central nervous system ( CNS ) malignant disease subject history CNS malignancy . Subjects stable , prior , currently treat brain metastasis allow . Known positive human immunodeficiency virus ( HIV ) , hepatitis B virus surface antigen ( HBsAg ) hepatitis C virus ( HCV ) Known autoimmune disease Active infection require intravenous ( IV ) antibiotic usage within last week prior dosimetry portion study Corticosteroid use within 2 week study treatment Any medical intervention condition , opinion Principal Investigator , could compromise adherence study requirement confound interpretation study result Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>